Despite the potential of genomic testing and targeted therapies to transform non-small cell lung cancer (NSCLC) care, underuse and delays often prevent patients from fully benefiting. Studies reveal that many patients lack biomarker testing or receive inappropriate therapies, undermining outcomes. By adopting liquid biomarker testing and lab values management (LVM), healthcare systems can streamline diagnosis and treatment, reducing delays and improving care quality.

In this KevinMD article, Avalon Vice President of Product Matt Ingram and Product Manager Mike Dovidio, PharmD, detail how automated processes, such as prior authorizations and tumor mutation matching, enable faster, more accurate treatment decisions, leading to better patient outcomes and lower costs. This innovative approach is setting a new standard for integrating advanced testing into cancer care.

Read the full article at KevinMD.